Childhood vaccine schedule updated (w/ Video)

January 7, 2010

The co-director of the University of Alabama at Birmingham (UAB) Division of Pediatric Infectious Diseases is a member of the committee that this week issued updated guidelines for childhood and teen immunizations to include formal recommendations that children older than 6 months get the H1N1 influenza vaccine to guard against swine flu, and that combination vaccines are generally preferred over separate injections.

The revised childhood vaccine schedule is published in the January issue of Pediatrics; the annual update is issued by the American Academy of Pediatrics, the and the American Academy of Family Physicians.

UAB's David Kimberlin, M.D., is a member of the American Academy of Pediatrics Committee on Infectious Diseases and a liaison to the Centers for Disease Control panel that helped author the recommendations.

David Kimberlin, M.D. serves on the panel that released new childhood vaccine schedules. Credit: UAB

"Most of these recommendations are for vaccines and boosters that almost every pediatrician and family physician knows about and already is using. It is good practice to issue a clear, concise vaccine schedule that anyone can refer to," says Kimberlin, a UAB professor and associate editor of the American Academy of Pediatrics' Red Book, a revered pediatric treatment manual.

"The bottom line here is vaccines save lives, improve the health of all children and benefit families and communities," he says.

The updated schedule reflects new vaccines approved by the U.S. that include the H1N1 vaccine and a for girls, known as the HPV2 vaccine, designed to protect females from two strains of the virus associated with more than 70 percent of cervical cancer cases, says Kimberlin.

The new schedule states it is permissible for doctors to recommend the earlier HPV4 vaccine for boys ages 9 and older, offering protection from four strains of the virus and reducing the likelihood of male genital warts. The recommendations also say children considered at-risk for meningococcal disease, especially those with immune-system disorders and other conditions, should get a booster shot of meningococcal conjugate vaccine, known as MCV4, three years after their initial MCV4 dose at ages 2 through 6.

The update also says that after four scheduled doses of inactivated poliovirus vaccine, the fifth dose of the same vaccine should be given on or after age 4 and at least six months after the previous dose.

Kimberlin says vaccine considerations always should consider health-care provider assessment, patient preference and the potential for adverse events. Providers who need more details should refer to the comprehensive recommendations issued by the Centers for Disease Control Advisory Committee on Immunization Practices, available by clicking here. Clinically significant adverse events that follow immunization should be reported to the Adverse Event Reporting System at www.vaers.hhs.gov or 800-822-7967.

Related Stories

Recommended for you

Glucocorticoids offer long-term benefits for patients with Duchenne muscular dystrophy

November 22, 2017
Glucocorticoids, a class of steroid hormone medications often prescribed to patients with Duchenne muscular dystrophy (DMD), offer long-term benefits for this disease, including longer preservation of muscle strength and ...

Baby-boomers and millennials more afflicted by the opioid epidemic

November 21, 2017
Baby-boomers, those born between 1947 and 1964, experienced an excess risk of prescription opioid overdose death and heroin overdose death, according to latest research at Columbia University's Mailman School of Public Health. ...

Sensor-equipped pill raises technological, ethical questions

November 17, 2017
The first drug with a sensor embedded in a pill that alerts doctors when patients have taken their medications was approved by the Food and Drug Administration, raiding issues involving privacy, cost, and whether patients ...

New painkillers reduce overdose risk

November 16, 2017
Scientists on the Florida campus of The Scripps Research Institute (TSRI) have developed new opioid pain relievers that reduce pain on par with morphine but do not slow or stop breathing—the cause of opiate overdose.

Separating side effects could hold key for safer opioids

November 16, 2017
Opioid pain relievers can be extremely effective in relieving pain, but can carry a high risk of addiction and ultimately overdose when breathing is suppressed and stops. Scientists have discovered a way to separate these ...

US regulators approve first digital pill to track patients

November 14, 2017
U.S. regulators have approved the first drug with a sensor that alerts doctors when the medication has been taken, offering a new way of monitoring patients but also raising privacy concerns.

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

marky
not rated yet Jan 08, 2010
One needs to look at both side of the coin to form a balanced and informed opinion on the safe use of vaccines.
Therefore see also:
http://articles.m...see.aspx

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.